- Varnell, Charles;
- Harshman, Lyndsay A;
- Liu, Chunyan;
- Smith, Laurie;
- Al-Akash, Samhar;
- Barletta, Gina-Marie;
- Brakeman, Paul;
- Chaudhuri, Abanti;
- Fadakar, Paul;
- Galea, Lauren;
- Garro, Rouba;
- Gluck, Caroline;
- Kershaw, David B;
- Matossian, Debora;
- Patel, Hiren P;
- Peterson, Caitlin;
- Pruette, Cozumel;
- Ranabothu, Saritha;
- Rodig, Nancy;
- Singer, Pamela;
- Sebestyen VanSickle, Judith;
- Weng, Patricia L;
- Danziger-Isakov, Lara;
- Seifert, Michael E;
- Hooper, David K
Background
We report follow-up data from an ongoing prospective cohort study of COVID-19 in pediatric kidney transplantation through the Improving Renal Outcomes Collaborative (IROC).Methods
Patient-level data from the IROC registry were combined with testing, indication, and outcomes data collected to describe the epidemiology of COVID testing, treatment, and clinical outcomes; determine the incidence of a positive COVID-19 test; describe rates of COVID-19 testing; and assess for clinical predictors of a positive COVID-19 test.Results
From September 2020 to February 2021, 21 centers that care for 2690 patients submitted data from 648 COVID-19 tests on 465 patients. Most patients required supportive care only and were treated as outpatients, 16% experienced inpatient care, and 5% experienced intensive care. Allograft complications were rare, with acute kidney injury most common (7%). There was 1 case of respiratory failure and 1 death attributed to COVID-19. Twelve centers that care for 1730 patients submitted complete testing data on 351 patients. The incidence of COVID-19 among patients at these centers was 4%, whereas the incidence among tested patients was 19%. Risk factors to predict a positive COVID-19 test included age > 12 years, symptoms consistent with COVID-19, and close contact with a confirmed case of COVID-19.Conclusions
Despite the increase in testing and positive tests over this study period, the incidence of allograft loss or death related to COVID-19 remained extremely low, with allograft loss or death each occurring in < 1% of COVID-19-positive patients and in less than < 0.1% of all transplant patients within the IROC cohort. A higher resolution version of the Graphical abstract is available as Supplementary information.